Sun Pharma Advanced Research Co
152.10
+0.55(+0.36%)
Market Cap₹- Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D+0.36%
1M+11.36%
6M-3.02%
1Y-30.69%
5Y-20.76%
View Company Insightsright
More news about Sun Pharma Advanced Research Co
04Jun 25
SPARC Shares Plummet 19% as Psoriasis Drug Fails Phase 2 Trials
Sun Pharma Advanced Research Company (SPARC) experienced a 19% drop in share price following the announcement that its experimental psoriasis treatment failed to meet objectives in Phase 2 clinical trials. This setback highlights the risks associated with drug development in the pharmaceutical industry and represents a significant challenge for SPARC's research pipeline.
04Jun 25
Sun Pharma Advanced Research Company: Psoriasis Drug Fails Phase 2 Trials, Shares Plummet
Sun Pharma Advanced Research Company (SPARC) has discontinued its investigational drug SCD-044 (Vibozilimod) for psoriasis and atopic dermatitis treatment after Phase 2 clinical trials failed to meet primary endpoints. The company's stock price dropped 20% to Rs 156.50 on the BSE following the announcement. This setback impacts SPARC's specialty pipeline and may lead to a reassessment of the company's drug development strategy.
12May 25
Sun Pharma Advanced Research to Discuss Fund Raising Proposal in Upcoming Board Meeting
Sun Pharma Advanced Research Company (SPARC) has announced a board meeting on May 19, 2023, to discuss and potentially approve a fund-raising proposal. While specific details are not yet disclosed, this initiative could significantly impact the company's financial strategy and future operations. Possible uses for the funds in the pharmaceutical sector typically include research and development, clinical trials, infrastructure expansion, debt reduction, or working capital enhancement.
31Mar 25
SPARC Advances Cancer Treatment: IND Application for SBO-154 Submitted to FDA
Sun Pharma Advanced Research Company (SPARC) has submitted an Investigational New Drug (IND) application for SBO-154 to the U.S. FDA. SBO-154 is an antibody-drug conjugate targeting MUC1 for advanced solid tumor treatment. The company plans to initiate global Phase 1 clinical trials, including dose-escalation and expansion phases, to evaluate the drug's safety and efficacy. This marks a significant milestone in SPARC's oncology pipeline development.
1 Year Returns:-30.69%
Industry Peers
Windlas Biotech
790.15
(+0.55%)
Jeena Sikho Lifecare
699.20
(+0.52%)
Blue Jet Healthcare
554.80
(-2.56%)
Abbott
28,850.00
(-0.14%)
Sunrest Lifescience
42.05
(-2.21%)
Zenith Drugs
54.60
(+2.25%)
Pfizer
5,001.00
(+0.57%)
FDC
414.10
(+0.24%)